C4 glomerulopathy historical perspective: Difference between revisions

Jump to navigation Jump to search
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
There is limited information about the historical perspective of C4 glomerulopathy.


==Historical Perspective==
==Historical Perspective==
Sethi and Fervenza introduced a new classification based on immunofluorescence results for complement and immunoglobulin deposition. The deposition could either be by dysregulation of the complement alternative pathway or by immune complexes such as C4 glomerulopathy. The morphological, phenotypic characteristics of C4 glomerulopathy may be either those categorized by dense osmiophilic deposits or those of C4 glomerulonephritis, which displays isolated depositsC4NeF was noticed in systemic lupus erythematosus, acute glomerulonephritis, and chronic proliferative glomerulonephritis and was also described in 100 hypocomplementemias MPGN patients with or without C3NeF.Sethi et al. defined C4d+ dominant Dense deposit disease wherein C3 was absent<ref name="pmid22435371">{{cite journal| author=Sethi S, Fervenza FC| title=Membranoproliferative glomerulonephritis--a new look at an old entity. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 12 | pages= 1119-31 | pmid=22435371 | doi=10.1056/NEJMra1108178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22435371  }} </ref><ref name="pmid6902727">{{cite journal| author=Halbwachs L, Leveillé M, Lesavre P, Wattel S, Leibowitch J| title=Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. | journal=J Clin Invest | year= 1980 | volume= 65 | issue= 6 | pages= 1249-56 | pmid=6902727 | doi=10.1172/jci109787 | pmc=371461 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6902727  }} </ref><ref name="pmid8306508">{{cite journal| author=Ohi H, Yasugi T| title=Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). | journal=Clin Exp Immunol | year= 1994 | volume= 95 | issue= 2 | pages= 316-21 | pmid=8306508 | doi=10.1111/j.1365-2249.1994.tb06530.x | pmc=1534915 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8306508  }} </ref><ref name="pmid2736802">{{cite journal| author=Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M| title=C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. | journal=Clin Exp Immunol | year= 1989 | volume= 76 | issue= 1 | pages= 82-5 | pmid=2736802 | doi= | pmc=1541731 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2736802  }} </ref><ref name="pmid6903579">{{cite journal| author=Daha MR, van Es LA| title=Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. | journal=J Immunol | year= 1980 | volume= 125 | issue= 5 | pages= 2051-4 | pmid=6903579 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6903579  }} </ref>.
Sethi and Fervenza introduced a new classification based on immunofluorescence results for complement and immunoglobulin deposition. The deposition could either be by dysregulation of the complement alternative pathway or by immune complexes such as C4 glomerulopathy. The morphological, phenotypic characteristics of C4 glomerulopathy may be either those categorized by dense osmiophilic deposits or those of C4 glomerulonephritis, which displays isolated deposits. C4NeF was noticed in systemic lupus erythematosus, acute glomerulonephritis, and chronic proliferative glomerulonephritis and was also described in 100 hypocomplementemias MPGN patients with or without C3NeF. Sethi et al. defined C4d+ dominant Dense deposit disease wherein C3 was absent<ref name="pmid22435371">{{cite journal| author=Sethi S, Fervenza FC| title=Membranoproliferative glomerulonephritis--a new look at an old entity. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 12 | pages= 1119-31 | pmid=22435371 | doi=10.1056/NEJMra1108178 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22435371  }} </ref><ref name="pmid6902727">{{cite journal| author=Halbwachs L, Leveillé M, Lesavre P, Wattel S, Leibowitch J| title=Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. | journal=J Clin Invest | year= 1980 | volume= 65 | issue= 6 | pages= 1249-56 | pmid=6902727 | doi=10.1172/jci109787 | pmc=371461 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6902727  }} </ref><ref name="pmid8306508">{{cite journal| author=Ohi H, Yasugi T| title=Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). | journal=Clin Exp Immunol | year= 1994 | volume= 95 | issue= 2 | pages= 316-21 | pmid=8306508 | doi=10.1111/j.1365-2249.1994.tb06530.x | pmc=1534915 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8306508  }} </ref><ref name="pmid2736802">{{cite journal| author=Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M| title=C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. | journal=Clin Exp Immunol | year= 1989 | volume= 76 | issue= 1 | pages= 82-5 | pmid=2736802 | doi= | pmc=1541731 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2736802  }} </ref><ref name="pmid6903579">{{cite journal| author=Daha MR, van Es LA| title=Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. | journal=J Immunol | year= 1980 | volume= 125 | issue= 5 | pages= 2051-4 | pmid=6903579 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6903579  }} </ref>.


==References==
==References==

Latest revision as of 05:05, 6 August 2020

C4 glomerulopathy Microchapters

Complement Mediated Glomerular Disorders Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating C4 glomerulopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

C4 glomerulopathy historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of C4 glomerulopathy historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on C4 glomerulopathy historical perspective

CDC on C4 glomerulopathy historical perspective

C4 glomerulopathy historical perspective in the news

Blogs on C4 glomerulopathy historical perspective

Directions to Hospitals Treating C4 glomerulopathy

Risk calculators and risk factors for C4 glomerulopathy historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Ali Poyan Mehr, M.D. [2]; Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]

Overview

There is limited information about the historical perspective of C4 glomerulopathy.

Historical Perspective

Sethi and Fervenza introduced a new classification based on immunofluorescence results for complement and immunoglobulin deposition. The deposition could either be by dysregulation of the complement alternative pathway or by immune complexes such as C4 glomerulopathy. The morphological, phenotypic characteristics of C4 glomerulopathy may be either those categorized by dense osmiophilic deposits or those of C4 glomerulonephritis, which displays isolated deposits. C4NeF was noticed in systemic lupus erythematosus, acute glomerulonephritis, and chronic proliferative glomerulonephritis and was also described in 100 hypocomplementemias MPGN patients with or without C3NeF. Sethi et al. defined C4d+ dominant Dense deposit disease wherein C3 was absent[1][2][3][4][5].

References

  1. Sethi S, Fervenza FC (2012). "Membranoproliferative glomerulonephritis--a new look at an old entity". N Engl J Med. 366 (12): 1119–31. doi:10.1056/NEJMra1108178. PMID 22435371.
  2. Halbwachs L, Leveillé M, Lesavre P, Wattel S, Leibowitch J (1980). "Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme". J Clin Invest. 65 (6): 1249–56. doi:10.1172/jci109787. PMC 371461. PMID 6902727.
  3. Ohi H, Yasugi T (1994). "Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN)". Clin Exp Immunol. 95 (2): 316–21. doi:10.1111/j.1365-2249.1994.tb06530.x. PMC 1534915. PMID 8306508.
  4. Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M (1989). "C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis". Clin Exp Immunol. 76 (1): 82–5. PMC 1541731. PMID 2736802.
  5. Daha MR, van Es LA (1980). "Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein". J Immunol. 125 (5): 2051–4. PMID 6903579.

Template:WHTemplate:WS